"FLT3-Positive" Doesn't Mean the Same Thing Everywhere. Romania's AML Testing Landscape Proved It
The barrier
A criterion like “FLT3-mutated AML, confirmed via molecular testing” reads as one universal bar. In Romania, it isn’t. AML diagnosis combines conventional karyotyping and FISH for chromosomal abnormalities – t(15;17)(q24;q21) is the most common structural anomaly found in Romanian AML patients – with a separate panel (PCR, RT-qPCR, and increasingly NGS) to identify mutations like FLT3, NPM1, CEBPA, IDH1/2, RUNX1, and DNMT3A. FLT3 testing specifically is a required prerequisite for treatment with midostaurin, yet testing depth still varies by method and by site. The result: a significant number of Romanian AML patients can’t be fully risk-stratified.
The insight
Patient Journey data surfaces this mismatch at the protocol design stage, before it becomes a recruitment problem. Instead of treating “FLT3-mutated” as a criterion that simply filters patients once they reach a site, it shows where the criterion collides with a country’s actual diagnostic infrastructure, emptying the eligible pool long before a single patient is screened.
The outcome
Sponsors can see whether a biomarker-driven criterion is realistically testable at the scale a Romanian AML trial needs, and adjust accordingly: accept PCR/RT-qPCR alongside NGS, treat testing capability as a site-selection factor, or size enrollment projections to the real, risk-stratified population instead of the theoretical one.
Impact on client: Eligibility and patient profiling